SYRE: financial statements from SEC — TradeAlmanac

SYRE

Spyre Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	—	—	—	—	0	0
Selling, general and administrative	15m	12m	12m	12m	11m	12m
Operating expenses	46m	57m	42m	54m	55m	44m
Operating income	−46m	−57m	−42m	−54m	−55m	−44m
Pre-tax income	−69m	−11m	−37m	−45m	−69m	−39m
Income tax	0	0	0	−15,000	18,000	0
Net income	−69m	−11m	−37m	−45m	−69m	−39m
Earnings per share	—	—	—	—	1.06	0.59
Earnings per share, diluted	−0.74	—	—	—	1.06	0.59
Weighted average shares	—	—	—	—	51m	45m
Weighted average shares, diluted	—	—	—	—	51m	45m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	97m	86m	65m	82m	48m	89m	72m	45m
Current assets	764m	778m	505m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Operating cash flow	−57m	−41m	—	—
Share-based compensation	13m	9m	13m	9m
Investing cash flow	57m	−61,000	—

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)